Cargando…
Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity
Cisplatin, one of the most active anticancer agents, is widely used in standard chemotherapy for various cancers. Cisplatin is more poorly tolerated than other chemotherapeutic drugs, and the main dose-limiting toxicity of cisplatin is its nephrotoxicity, which is dose-dependent. Although less toxic...
Autores principales: | Arita, Masashi, Watanabe, Satoshi, Aoki, Nobumasa, Kuwahara, Shoji, Suzuki, Ryo, Goto, Sawako, Abe, Yuko, Takahashi, Miho, Sato, Miyuki, Hokari, Satoshi, Ohtsubo, Aya, Shoji, Satoshi, Nozaki, Koichiro, Ichikawa, Kosuke, Kondo, Rie, Hayashi, Masachika, Ohshima, Yasuyoshi, Kabasawa, Hideyuki, Hosojima, Michihiro, Koya, Toshiyuki, Saito, Akihiko, Kikuchi, Toshiaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7804437/ https://www.ncbi.nlm.nih.gov/pubmed/33437029 http://dx.doi.org/10.1038/s41598-020-80853-6 |
Ejemplares similares
-
Correlation of prechemotherapy urinary megalin ectodomain (A-megalin) levels with the development of cisplatin-induced nephrotoxicity: a prospective observational study
por: Shoji, Satoshi, et al.
Publicado: (2019) -
Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors
por: Sato, Ko, et al.
Publicado: (2016) -
Prognostic significance of procalcitonin in small cell lung cancer
por: Ichikawa, Kosuke, et al.
Publicado: (2022) -
Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations
por: Sato, Miyuki, et al.
Publicado: (2019) -
Effect of Cilastatin on Cisplatin-Induced Nephrotoxicity in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy
por: Zaballos, Matilde, et al.
Publicado: (2021)